Lessons from Prasad’s ouster at FDA, and what’s next for Novo, Bayer — a BioCentury podcast

Plus: Promising data behind a new wave masked biologics promises 

The ouster of Vinay Prasad after three months running FDA’s Center for Biologics Evaluation and Research could signal a reset is ahead for CBER. On the latest BioCentury This Week podcast, BioCentury’s analysts discuss what the latest shakeup at the regulatory agency says about where FDA is headed.

The analysts also assess two leading European pharmas: obesity and diabetes company Novo Nordisk A/S (CSE:NOVO B; NYSE:NVO), which named a new CEO last week while cutting its 2025 forecast, and Bayer AG (Xetra:BAYN), which is gearing up for launches and is revamping its pipeline to restart growth.

Finally, they discuss the promising clinical data that’s reviving interest in masking technologies to conditionally activate biologics.